SEC Form 4 · Rule 10b5-1 trading plans

Spyre Therapeutics, Inc. (SYRE)

76Trades filed under a plan
4Plan adoption dates stated
0Quarterly results prints on file
0Trades in the days before a print

In the 2025 filing year, Spyre Therapeutics, Inc. filed 26 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 6 reporting owners, covering 76 transactions filed under those plans and 520,089 shares. None carries the SEC's own AFF10B5ONE adoption flag; each of the 26 names a plan in a footnote. No results print is on file in this window, so no interval is measured.

Trades filed under a plan in Spyre Therapeutics, Inc. 76

Plan adoption dates stated in Spyre Therapeutics, Inc. 4

Quarterly results prints on file in Spyre Therapeutics, Inc. 0

Trades in the days before a print in Spyre Therapeutics, Inc. 0

Interval to the next reported results date

For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.

0Within 5 days of a print
0Within 10 days of a print
—Shortest interval, in days
76Trades with no later print on file

Adoption dates, as the filings state them

As the filings state it: “10b5-1 trading plan adopted on June 20, 2025”

Every company with plan records →

Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.

The Pay Desk is the free weekly executive pay briefing — one company at a time, every number traceable to a public filing.We’ll email you a link to confirm. Unsubscribe any time.